Selectivity and Anti-Parkinsons Potential of Thiadiazolidinone RGS4 Inhibitors

ACS Chemical Neuroscience

Volumn 6, Issue 6, 2015, Pages 911-919

  Blazer, Levi L ^a,b   Storaska, Andrew J ^a,b   Jutkiewicz, Emily M ^a   Turner, Emma M ^c   Calcagno, Mariangela ^d   Wade, Susan M ^a   Wang, Qin ^a   Huang, Xi Ping ^e   Traynor, John R ^a   Husbands, Stephen M ^c   Morari, Michele ^d   Neubig, Richard R ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c University of Bath   (United Kingdom)

^d UNIVERSITY OF FERRARA   (Italy)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Parkinsons disease; PPI; protein protein interaction; Regulator of G protein signaling; RGS; thiadiazolidinone

Indexed keywords

ANTIPARKINSON AGENT; CALCIUM ION; CCG 203769; CYCLIC AMP; CYSTEINE PROTEINASE; GLYCOGEN SYNTHASE KINASE 3BETA; PAPAIN; PROTEIN INHIBITOR; RACLOPRIDE; RGS PROTEIN; RGS4 PROTEIN; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; CALCIUM; CARBACHOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN; GSK3B PROTEIN, MOUSE; GSK3B PROTEIN, RAT;

ADULT; AKINESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRADYCARDIA; BRADYKINESIA; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CELL LINE; CONTROLLED STUDY; DRUG BINDING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC50; MALE; MOTOR DYSFUNCTION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIPARKINSON AGENTS; BRADYCARDIA; CALCIUM; CARBACHOL; CELL LINE, TUMOR; CHOLINERGIC AGONISTS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HEK293 CELLS; HUMANS; MALE; MICE, INBRED C57BL; MOTOR ACTIVITY; PAPAIN; PARKINSONIAN DISORDERS; RACLOPRIDE; RATS, SPRAGUE-DAWLEY; RGS PROTEINS;

EID: 84935011200     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/acschemneuro.5b00063     Document Type: Article

References (46)

1. Carrieri, A., Perez-Nueno, V. I., Lentini, G., and Ritchie, D. W. (2013) Recent trends and future prospects in computational GPCR drug discovery: from virtual screening to polypharmacology Curr. Top. Med. Chem. 13, 1069-1097
2. Nickols, H. H. and Conn, P. J. (2014) Development of allosteric modulators of GPCRs for treatment of CNS disorders Neurobiol. Dis. 61, 55-71
3. Shonberg, J., Lopez, L., Scammells, P. J., Christopoulos, A., Capuano, B., and Lane, J. R. (2014) Biased agonism at G protein-coupled receptors: The promise and the challenges-A medicinal chemistry perspective Med. Res. Rev. 34, 1286-1330
4. Congreve, M., Dias, J. M., and Marshall, F. H. (2014) Structure-based drug design for G protein-coupled receptors Prog. Med. Chem. 53, 1-63
5. Hollenstein, K., de Graaf, C., Bortolato, A., Wang, M. W., Marshall, F. H., and Stevens, R. C. (2014) Insights into the structure of class B GPCRs Trends Pharmacol. Sci. 35, 12-22
6. Christopoulos, A. (2014) Advances in G protein-coupled receptor allostery: From function to structure Mol. Pharmacol. 86, 463-478
7. Blazer, L. L. and Neubig, R. R. (2009) Small molecule protein-protein interaction inhibitors as CNS therapeutic agents: current progress and future hurdles Neuropsychopharmacology 34, 126-141
8. Neubig, R. R. and Siderovski, D. P. (2002) Regulators of G-protein signalling as new central nervous system drug targets Nat. Rev. Drug Discovery 1, 187-197
9. Sjogren, B., Blazer, L. L., and Neubig, R. R. (2010) Regulators of G protein signaling proteins as targets for drug discovery Prog. Mol. Biol. Transl Sci. 91, 81-119
10. Traynor, J. R. and Neubig, R. R. (2005) Regulators of G protein signaling & drugs of abuse Mol. Interventions 5, 30-41
11. Bodle, C. R., Mackie, D. I., and Roman, D. L. (2013) RGS17: an emerging therapeutic target for lung and prostate cancers Future Med. Chem. 5, 995-1007
12. Kimple, A. J., Bosch, D. E., Giguere, P. M., and Siderovski, D. P. (2011) Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets Pharmacol Rev. 63, 728-749
13. Sjogren, B. (2011) Regulator of G protein signaling proteins as drug targets: current state and future possibilities Adv. Pharmacol. 62, 315-347
14. Chen, Y., Liu, Y., Cottingham, C., McMahon, L., Jiao, K., Greengard, P., and Wang, Q. (2012) Neurabin scaffolding of adenosine receptor and RGS4 regulates anti-seizure effect of endogenous adenosine J. Neurosci. 32, 2683-2695
15. Lerner, T. N. and Kreitzer, A. C. (2012) RGS4 is required for dopaminergic control of striatal LTD and susceptibility to Parkinsonian motor deficits Neuron 73, 347-359
16. Ko, W. K., Martin-Negrier, M. L., Bezard, E., Crossman, A. R., and Ravenscroft, P. (2014) RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinsons disease Neurobiol. Dis. 70, 138-148
17. Azzarito, V., Long, K., Murphy, N. S., and Wilson, A. J. (2013) Inhibition of alpha-helix-mediated protein-protein interactions using designed molecules Nat. Chem. 5, 161-173
18. London, N., Raveh, B., and Schueler-Furman, O. (2013) Druggable protein-protein interactions - from hot spots to hot segments Curr. Opin Chem. Biol. 17, 952-959
19. Voet, A., Banwell, E. F., Sahu, K. K., Heddle, J. G., and Zhang, K. Y. (2013) Protein interface pharmacophore mapping tools for small molecule protein: protein interaction inhibitor discovery Curr. Top Med. Chem. 13, 989-1001
20. Morelli, X., Bourgeas, R., and Roche, P. (2011) Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I) Curr. Opin. Chem. Biol. 15, 475-481
21. Mullard, A. (2012) Protein-protein interaction inhibitors get into the groove Nat. Rev. Drug Discovery 11, 173-175
22. Villoutreix, B. O., Labbe, C. M., Lagorce, D., Laconde, G., and Sperandio, O. (2012) A leap into the chemical space of protein-protein interaction inhibitors Curr. Pharm. Des. 18, 4648-4667
23. Kalgutkar, A. S. and Dalvie, D. K. (2012) Drug discovery for a new generation of covalent drugs Expert Opin. Drug Discovery 7, 561-581
24. Lopez-Tarruella, S., Jerez, Y., Marquez-Rodas, I., and Martin, M. (2012) Neratinib (HKI-272) in the treatment of breast cancer Future Oncol. 8, 671-681
25. Blazer, L. L., Zhang, H., Casey, E. M., Husbands, S. M., and Neubig, R. R. (2011) A nanomolar-potency small molecule inhibitor of regulator of G protein signaling (RGS) proteins Biochemistry 50, 3181-3192
26. Turner, E. M., Blazer, L. L., Neubig, R. R., and Husbands, S. M. (2012) Small molecule inhibitors of regulator of G protein signalling (RGS) proteins ACS Med. Chem. Lett. 3, 146-150
27. Rosa, A. O., Kaster, M. P., Binfare, R. W., Morales, S., Martin-Aparicio, E., Navarro-Rico, M. L., Martinez, A., Medina, M., Garcia, A. G., Lopez, M. G., and Rodrigues, A. L. (2008) Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1549-1556
28. Castro, A., Encinas, A., Gil, C., Brase, S., Porcal, W., Perez, C., Moreno, F. J., and Martinez, A. (2008) Non-ATP competitive glycogen synthase kinase 3beta (GSK-3beta) inhibitors: study of structural requirements for thiadiazolidinone derivatives Bioorg. Med. Chem. 16, 495-510
29. Martinez, A., Alonso, M., Castro, A., Perez, C., and Moreno, F. J. (2002) First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimers disease J. Med. Chem. 45, 1292-1299
30. Wang, Q., Liu-Chen, L. Y., and Traynor, J. R. (2009) Differential modulation of mu- and delta-opioid receptor agonists by endogenous RGS4 protein in SH-SY5Y cells J. Biol. Chem. 284, 18357-18367
31. Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X. P., Norval, S., Sassano, M. F., Shin, A. I., Webster, L. A., Simeons, F. R., Stojanovski, L., Prat, A., Seidah, N. G., Constam, D. B., Bickerton, G. R., Read, K. D., Wetsel, W. C., Gilbert, I. H., Roth, B. L., and Hopkins, A. L. (2012) Automated design of ligands to polypharmacological profiles Nature 492, 215-220
32. Fenalti, G., Giguere, P. M., Katritch, V., Huang, X. P., Thompson, A. A., Cherezov, V., Roth, B. L., and Stevens, R. C. (2014) Molecular control of delta-opioid receptor signalling Nature 506, 191-196
33. Wu, H., Wacker, D., Mileni, M., Katritch, V., Han, G. W., Vardy, E., Liu, W., Thompson, A. A., Huang, X. P., Carroll, F. I., Mascarella, S. W., Westkaemper, R. B., Mosier, P. D., Roth, B. L., Cherezov, V., and Stevens, R. C. (2012) Structure of the human kappa-opioid receptor in complex with JDTic Nature 485, 327-332
34. Cifelli, C., Rose, R. A., Zhang, H., Voigtlaender-Bolz, J., Bolz, S. S., Backx, P. H., and Heximer, S. P. (2008) RGS4 regulates parasympathetic signaling and heart rate control in the sinoatrial node Circ. Res. 103, 527-535
35. Vashisth, H., Storaska, A. J., Neubig, R. R., and Brooks, C. L., III (2013) Conformational dynamics of a regulator of G-protein signaling protein reveals a mechanism of allosteric inhibition by a small molecule ACS Chem. Biol. 8, 2778-2784
36. Fu, Y., Huang, X., Zhong, H., Mortensen, R. M., DAlecy, L. G., and Neubig, R. R. (2006) Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects Circ. Res. 98, 659-666
37. Roman, D. L., Ota, S., and Neubig, R. R. (2009) Polyplexed flow cytometry protein interaction assay: A novel high-throughput screening paradigm for RGS protein inhibitors J. Biomol Screen 14, 610-619
38. Storaska, A. J., Mei, J. P., Wu, M., Li, M., Wade, S. M., Blazer, L. L., Sjogren, B., Hopkins, C. R., Lindsley, C. W., Lin, Z., Babcock, J. J., McManus, O. B., and Neubig, R. R. (2013) Reversible inhibitors of regulators of G-protein signaling identified in a high-throughput cell-based calcium signaling assay Cell. Signal. 25, 2848-2855
39. Blazer, L. L., Roman, D. L., Muxlow, M. R., and Neubig, R. R. (2010) Use of flow cytometric methods to quantify protein-protein interactions. Curr. Protoc. Cytom., Chapter 13, Unit 13.11, pp 11-15.
40. Roman, D. L., Talbot, J. N., Roof, R. A., Sunahara, R. K., Traynor, J. R., and Neubig, R. R. (2007) Identification of small-molecule inhibitors of RGS4 using a high-throughput flow cytometry protein interaction assay Mol. Pharmacol. 71, 169-175
41. Zielinski, T., Kimple, A. J., Hutsell, S. Q., Koeff, M. D., Siderovski, D. P., and Lowery, R. G. (2009) Two Galpha(i1) rate-modifying mutations act in concert to allow receptor-independent, steady-state measurements of RGS protein activity J. Biomol Screening 14, 1195-1206
42. Chang, L., Bertelsen, E. B., Wisen, S., Larsen, E. M., Zuiderweg, E. R., and Gestwicki, J. E. (2008) High-throughput screen for small molecules that modulate the ATPase activity of the molecular chaperone DnaK Anal. Biochem. 372, 167-176
43. Marti, M., Trapella, C., Viaro, R., and Morari, M. (2007) The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway J. Neurosci. 27, 1297-1307
44. Viaro, R., Sanchez-Pernaute, R., Marti, M., Trapella, C., Isacson, O., and Morari, M. (2008) Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism Neurobiol. Dis. 30, 430-438
45. Sanberg, P. R., Bunsey, M. D., Giordano, M., and Norman, A. B. (1988) The catalepsy test: its ups and downs Behav. Neurosci. 102, 748-759
46. Schallert, T., De Ryck, M., Whishaw, I. Q., Ramirez, V. D., and Teitelbaum, P. (1979) Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism Exp. Neurol. 64, 33-43